Table 3.
Comparison of number of genes annotated to phenotypes in downstream pathways.
| ID | Terma | Lactate | Glycolysis | Acetyl-CoA |
|---|---|---|---|---|
| Phenotypes with more genes in the glucose to lactate pathway (anaerobic) than glucose to pyruvate | ||||
| MP:0002447 | Abnormal erythrocyte morphology | 5 (5.24E−02) | 4 (4.55E−02) | 4 (1.51E−01) |
| MP:0002875 | Decreased erythrocyte cell number | 3 (3.71E−02) | 2 (6.79E−02) | 2 (1.51E−01) |
| MP:0000208 | Decreased hematocrit | 4 (4.21E−03) | 3 (1.11E−03) | 3 (3.37E−02) |
| MP:0005563 | Abnormal hemoglobin content | 4 (8.64E−03) | 3 (1.74E−02) | 3 (5.74E−02) |
| MP:0002874 | Decreased hemoglobin content | 3 (2.69E−02) | 2 (5.21E−02) | 2 (1.27E−01) |
| MP:0002590 | Increased mean corpuscular volume | 3 (2.03E−02) | 2 (4.65E−02) | 2 (1.07E−01) |
| MP:0013707 | Abnormal hematopoietic precursor cell morphology | 3 (3.82E−02) | 2 (7.01E−02) | 2 (1.51E−01) |
| MP:0001585 | Hemolytic anemia | 3 (4.06E−04) | 2 (6.18E−03) | 2 (1.74E−02) |
| MP:0002640 | Reticulocytosis | 4 (2.10E−04) | 3 (1.94E−03) | 3 (7.40E−03) |
| MP:0005344 | Increased circulating bilirubin level | 4 (7.85E−04) | 3 (4.60E−03) | 3 (1.69E−02) |
| MP:0000598 | Abnormal liver morphology | 6 (2.15E−02) | 4 (4.65E−02) | 4 (1.67E−01) |
| MP:0002221 | Abnormal lymph organ size | 5 (7.50E−02) | 4 (4.82E−02) | 4 (1.84E−01) |
| MP:0004952 | Increased spleen weight | 3 (2.15E−02) | 2 (4.82E−02) | 2 (1.12E−01) |
| MP:0012106 | Impaired exercise endurance | 2 (3.71E−02) | 1 (1.11E−01) | 1 (1.92E−01) |
| MP:0005584 | Abnormal enzyme/coenzyme activity | 4 (4.21E−03) | 3 (1.11E−02) | 3 (3.37E−02) |
| MP:0002942 | Decreased circulating alanine transaminase level | 2 (2.69E−02) | 0 (NA) | 0 (NA) |
| MP:0002943 | Abnormal lactate dehydrogenase level | 2 (2.32E−02) | 1 (9.55E−02) | 1 (1.66E−01) |
| Phenotypes with more genes in the glucose to acetyl-CoA pathway (aerobic) than glucose to pyruvate | ||||
| MP:0030970 | Ketosis | 1 (1.44E−01) | 1 (8.22E−02) | 3 (2.23E−03) |
| MP:0002575 | Increased circulating ketone body level | 0 (NA) | 0 (NA) | 2 (1.74E−02) |
| MP:0003059 | Decreased insulin secretion | 2 (5.96E−02) | 2 (3.76E−02) | 3 (1.31E−02) |
| MP:0005293 | Impaired glucose tolerance | 3 (6.56E−02) | 3 (2.78E−02) | 5 (7.40E−03) |
| MP:0013403 | Abnormal circulating lactate level | 1 (1.37E−01) | 1 (7.91E−02) | 3 (2.23E−03) |
| MP:0013405 | Increased circulating lactate level | 0 (NA) | 0 (NA) | 2 (1.21E−02) |
| MP:0001325 | Abnormal retina morphology | 2 (3.08E−01) | 2 (1.62E−01) | 5 (3.20E−02) |
| MP:0003731 | Abnormal retina outer nuclear layer morphology | 2 (1.07E−01) | 2 (4.93E−02) | 3 (2.50E−02) |
| MP:0008931 | Abnormal paraventricular thalamic nucleus morphology | 0 (NA) | 0 (NA) | 1 (1.98E−02) |
| MP:0004079 | Abnormal putamen morphology | 0 (NA) | 0 (NA) | 1 (4.09E−02) |
| MP:0020554 | Decreased stria medullaris size | 0 (NA) | 0 (NA) | 1 (2.50E−02) |
| MP:0009976 | Abnormal cerebellar peduncle morphology | 0 (NA) | 0 (NA) | 1 (4.60E−02) |
| MP:0003984 | Embryonic growth retardation | 1 (4.79E−01) | 1 (3.24E−01) | 4 (3.20E−02) |
| Phenotypes with more genes in both the lactate/acetyl-CoA pathways than in glucose to pyruvate | ||||
| MP:0000187 | Abnormal triglyceride level | 3 (1.00E−01) | 2 (1.10E−01) | 4 (4.09E−02) |
| MP:0005318 | Decreased triglyceride level | 2 (1.38E−01) | 1 (2.20E−01) | 3 (4.14E−02) |
| MP:0002078 | Abnormal glucose homeostasis | 4 (1.59E−01) | 3 (1.16E−01) | 7 (2.02E−02) |
| MP:0005291 | Abnormal glucose tolerance | 4 (3.98E−02) | 3 (4.65E−02) | 6 (7.40E−03) |
| MP:0001560 | Abnormal circulating insulin level | 3 (7.85E−02) | 2 (9.49E−02) | 4 (2.50E−02) |
| MP:0002727 | Decreased circulating insulin level | 3 (2.69E−02) | 2 (5.22E−02) | 3 (3.20E−02) |
| MP:0002080 | Prenatal lethality | 5 (1.59E−01) | 3 (1.99E−01) | 8 (2.60E−02) |
| MP:0005266 | Abnormal metabolism | 6 (4.14E−03) | 4 (1.74E−02) | 5 (2.50E−02) |
| MP:0010768 | Mortality/aging | 9 (1.57E−01) | 7 (7.09E−02) | 14 (1.31E−02) |
| MP:0010769 | Abnormal survival | 8 (1.74E−01) | 6 (1.00E−01) | 13 (1.63E−02) |
| MP:0008762 | Embryonic lethality | 4 (1.74E−01) | 3 (1.34E−01) | 8 (1.31E−02) |
| MP:0010770 | Preweaning lethality | 8 (1.35E−01) | 3 (1.11E−01) | 13 (7.40E−03) |
| MP:0011100 | Preweaning lethality, complete penetrance | 4 (1.57E−01) | 3 (1.11E−01) | 6 (4.60E−02) |
If a parent MP term and its child were annotated to the same numbers of terms, only the child term is shown. For example, “abnormal insulin secretion” (parent—not shown) and “decreased insulin secretion” (child—shown) had 2,2,3 terms.